Funding for this research was provided by:
GlaxoSmithKline (China) R&D Company Limited
Text and Data Mining valid from 2019-04-11
Received: 24 November 2018
Accepted: 13 March 2019
First Online: 11 April 2019
Compliance with ethical standards
: Jinlin Hou has received consulting fees and grant/research support from Bristol-Myers Squibb, GlaxoSmithKline, Novartis and Roche. Qin Ning has received consulting fees and grant/research support from Bristol-Myers Squibb, GlaxoSmithKline, MSD, Novartis and Roche. Wenyan Zhang and Cui Xiong are employees of GlaxoSmithKline. All other authors have no conflict of interest to disclose.
: The study protocol was approved by an independent ethics committee or institutional review board at each study site. The study was conducted in accordance with the ethical principles laid down in the Declaration of Helsinki.
: Patients provided written informed consent for the open-label phase at the time of enrollment in the double-blind phase.
: Anonymized individual participant data and study documents can be requested for further research from ExternalRef removed.